• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Nektar Therapeutics (NQ: NKTR )

    1.005 -0.025 (-2.43%)
    Streaming Delayed Price Updated: 11:47 AM EST, Nov 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Nektar Therapeutics

    < Previous 1 2 3 4 5 Next >
    Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
    Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG's Treg-focused action as a potential breakthrough for Alopecia areata treatment. 
    Via Benzinga
    10 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    NKTR Stock Earnings: Nektar Therapeutics Misses EPS, Beats Revenue for Q2 2024
    NKTR stock results show that Nektar Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    NKTR Stock Earnings: Nektar Therapeutics Meets EPS, Beats Revenue for Q1 2024
    NKTR stock results show that Nektar Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Sweet Nektar?
    NKTR has had a terrible time of it for years, but maybe it’s finally ready to turn around. 
    Via Talk Markets
    Nektar Therapeutics Earnings Preview
    Via Benzinga
    Recap: Nektar Therapeutics Q3 Earnings
    Via Benzinga
    A Preview Of Nektar Therapeutics's Earnings
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Biotech's Lawsuit With Eli Lilly Might Catalyze Stock
    Nektar Therapeutics commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin, in patients with severe to very severe alopecia areata, a disease-causing patchy hair... 
    Via Talk Markets
    Topics Lawsuit
    Exposures Financial Legal
    Earnings Scheduled For March 4, 2024
    Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its fourth quarter. 
    Via Benzinga
    Expert Ratings for Nektar Therapeutics
    Via Benzinga
    Nektar Therapeutics: Q1 Earnings Insights
    Via Benzinga
    Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its... 
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    The One-Minute Market Report - Saturday, Aug. 12
    In this weekly outlook, I examine the asset classes, sectors, and ETFs that led the market higher, and which market segments bucked the trend by moving lower. Signs that market participation is... 
    Via Talk Markets
    Topics ETFs
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Why Is Nektar Therapeutics Stock Surging Today?
    Nektar Therapeutics Inc (NASDAQ: NKTR) said its former partner Eli Lilly And Co (NYSE: LLY) had presented "erroneous data" from two Phase 1b studies of its atopic dermatitis drug,  
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
    Via Benzinga
    Tempur Sealy International To Rally Around 32%? Here Are 10 Other Analyst Forecasts For Wednesday
    Keybanc raised the price target for Tempur Sealy International, Inc. (NYSE: TPX) from $48 to $50. Keybanc analyst Bradley Thomas maintained an Overweight rating. Tempur Sealy International shares rose... 
    Via Benzinga
    Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions
    Via Benzinga
    7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
    You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards. 
    Via InvestorPlace
    Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials
    This month, H.C. Wainwright & Co. 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Tuesday
      On Tuesday, 74 companies achieved new lows for the year. 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Tuesday
      Tuesday's morning session saw 84 companies set new 52-week lows. 
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.